美国制药行业游说组织PhRMA将推处方药直销平台 以应对特朗普降药价压力
智通财经网·2025-09-29 22:24

Core Insights - The pharmaceutical industry lobbying group PhRMA plans to launch a new website, AmericasMedicines.com, in January 2025 to enable patients to purchase prescription drugs directly from manufacturers, bypassing pharmacy benefit managers (PBMs) to reduce drug prices and simplify the purchasing process [1] - This initiative is a response to pressure from the Trump administration to lower U.S. drug prices, with President Trump having previously urged major pharmaceutical companies to align U.S. prescription drug prices with those of other developed countries [1] - The direct-to-consumer (DTC) sales model is gaining traction, with companies like Eli Lilly, Pfizer, and AstraZeneca launching their own platforms, and Novartis announcing a direct sales platform set to launch on November 1, offering significant discounts on certain medications [1] Industry Developments - PhRMA announced a total investment of $500 billion in domestic production and infrastructure, which is expected to generate $1.2 trillion in economic output and create over 100,000 jobs [2]